Depression is common, chronic, and costly. Up to 25% of women and 12% of men will experience depression, and once diagnosed, the likelihood of recurrence increases even when remission is initially achieved. Disability cost estimates related to depression were as high as $83 billion dollars in the United States alone in 2000. 1 Collaborative care management (CCM) has been shown through the IMPACT trial and other studies as an effective model for improving clinical outcomes for depression and for controlling longterm costs compared with usual care. [2] [3] [4] [5] Our group has studied cost utilization and clinical response using CCM compared with usual care as well as the correlation between mental health comorbidity and clinical response. Clinical response and remission rates have been shown to be significantly higher with CCM than compared to usual care. 6 The highest cost metrics were seen among those not responding by 6 months. 7 Others, in outpatient settings, have shown that patients with mental health comorbidities are less likely to reach remission of depression. 8, 9 Multiple studies addressing predictors of relapse of major depression have been evaluated in various practice settings. McGrath et al followed 570 patients with major
depression, cared for in a tertiary care center. Predictors of relapse in the 292 who achieved remission included greater chronicity of illness, greater symptom severity, a neurovegetative symptom pattern, and female gender. Panic disorder, social phobia, and alcohol dependence were not predictive of relapse. 10 In the STAR*D trial using both primary and psychiatric practice settings, Nierenberg et al found that in 943 out of 2876 patients achieving remission, those with a higher number of residual symptoms persisting after treatment (examples of symptom domains included sleep, sad mood, appetite/weight, concentration, outlook, energy) had a higher risk of relapse. 11 An outpatient assessment of 170 patients age 70 years and older by Andreescu et al found that patients with greater pretreatment anxiety had a longer time to remission and higher rates of recurrence. 12 Identifying predictors to treatment failure before they occur is critical as research indicates that subjective clinician ratings are poor predictors of final outcomes, and up to 40% of patients, rated by the clinician as in an improved state, are actually reporting more symptoms than when starting treatment. 13 In our literature review, we found only 1 study focusing on predictors of relapse in a primary care population and using CCM for treatment. Lin et al identified multiple predictors of relapse in a group of 251 primary care patients with depression. These predictors included subthreshold depressive symptoms 7 months past the start of treatment, a history of 2 or more episodes of major depression, chronic mood symptoms for 2 years, and a history of panic or generalized anxiety disorder. 14 Since March 2008, 411 patients have graduated from our CCM program and 41 were later readmitted. This was a retrospective review of the differences between those readmitted patients who had recurrent depression versus those who remained in remission for at least 4 months. Our hypothesis was that mental health comorbidities are more likely to be present in those patients who relapse with recurrent depression and would be readmitted into CCM.
Methods
In 2007, the Institute for Clinical Systems Improvement (ICSI), along with 5 clinical practices across the state of Minnesota, United States, and 6 commercial health care plans, spearheaded the development of a CCM for depression treatment. This Depression Initiative Across Minnesota Offering a New Direction (DIAMOND) model was intended to augment the relationship between the patient, primary care provider, and psychiatrist. The CCM model, developed by ICSI, allows for monthly payments by the major insurance companies in the state to the clinical sites for the CCM services for up to 1 year, or until the patient reaches remission. Since implementation in 2008, there have been a total of 83 clinics statewide that have begun offering CCM for depression.
Adult patients (age 18 and older) who were seen by a physician or midlevel provider at 1 of 2 primary care clinics (total patient population, 41 000) in Rochester, Minnesota, diagnosed with depression or dysthymia and had a PHQ-9 15 score of 10 or greater were eligible to be enrolled in CCM. The providers were from the Division of Primary Care Internal Medicine and Department of Family Medicine at Mayo Clinic Rochester. The patient population was community based and was approximately 50% employees or dependents of Mayo Clinic.
For the patients who met the enrollment criteria and accepted CCM, the initial evaluation by the RN care manager included a screening tool for alcoholism (AUDIT 16 ), anxiety (GAD-7 17 ), and mood disorders (MDQ 18 ). The CCM process involved weekly oversight by a psychiatrist, with medication or therapeutic changes managed by the primary care provider. Patient contact was dictated by the clinical scenario and PHQ-9 testing; some were contacted weekly, others monthly. Those patients reaching remission were graduated and attended relapse prevention counseling sessions. A patient may re-enter the program if they clinically relapse.
Since the CCM program was relatively new at the time of this review, a majority of the remitted patients were less than 4 months from the date of graduation. Only those records with complete intake data were utilized, leaving a total of 145 patients in the cohort. A total of 32 patients (22.1%) had been readmitted to CCM at the time of the data analysis and constituted our study group. The other 77.9% (N = 113) had completed CCM and had not been diagnosed with recurrent major depression (documented by a PHQ-9 score of <10) and were at least 120 days after graduation from CCM.
The dependent variable was the current status of the patient as either a graduate of CCM or readmission. The independent variables were age, gender, race, marital status, initial screening PHQ-9, GAD-7, MDQ and AUDIT scores, 6-month follow-up PHQ-9 score, reason for graduation from CCM, and length of time in CCM. The MDQ was scored as negative if the total was less than 6 and a negative response for both of the questions on concurrence and severity. Positive or partially positive MDQ scores were combined because of an insufficient sample size. For those patients who were readmitted, the length of time from initial graduation to readmission was calculated.
Since the data were not in a normal distribution, Mann-Whitney testing was performed for numerical variables. Categorical data were tested with chi-square analysis. Data were obtained from the database for the CCM project. Multiple logistic regression analysis was used to identify independent predictors of being readmitted for CCM. Included in the regression models were age, gender, marital status, race, initial and 6-month PHQ-9 score, AUDIT score, GAD-7 score, MDQ result, and length of treatment in CCM. The study was approved by the Institutional Review Board.
Results
There was no statistically significant difference in the 2 groups based on age, gender, race, marital status, initial screening PHQ-9 score, AUDIT score, percentage of negative MDQ scores, 6-month follow-up PHQ-9 scores, and reason for graduation from CCM ( Table 1 ). The average length of time in CCM was significantly higher in the readmission group (168.09 vs 120.99 days, P = .002) as was the initial GAD-7 score (12.81 vs 9.20, P = .001).
Multiple logistic regression was performed to control for the independent variables. When controlling for age, marital status, gender, race, initial PHQ-9 and AUDIT scores, and MDQ result, the days in CCM and intake GAD-7 score were significantly associated with those patients who were readmitted. The odds ratio for days of treatment in CCM was 1.0123 (CI = 1.0041 to 1.0206, P = .0033) and for GAD-7 was 1.1156 (CI = 1.0.192 to 1.2212, P = .0177) ( Table 2) .
Of the 32 patients who have been readmitted to CCM, the average length of time from graduation to readmission was 221.5 days (range, 17-464 days). The 113 patients in the remission group had a documented PHQ-9 < 10, on average, at 243.7 days after graduation (range, 120-343 days).
Discussion
Our original hypothesis for this article was partially correct. This study showed that patients readmitted to CCM had increased anxiety symptoms based on initial GAD-7 score and required longer duration of treatment to achieve remission than those who were still in remission for at least 4 months. Based on the above data, mood disorder screening and alcohol abuse screening were not associated with the cohort needing readmission. At the time of relapse prevention counseling, the care managers could adapt their counseling for patients who had elevated GAD-7 scores on initial intake. Additionally, those patients with prolonged treatment courses may alert the care manager and consulting psychiatrist to look more closely for ways to speed response and advise the patient about increased risk of relapse.
Once the patient has stable PHQ-9 scores < 5 for 8 weeks they are ready for graduation from CCM and can participate with the care manager in developing a relapse prevention plan. Because depressed patients with comorbid anxiety are more difficult to keep in remission, it is vital that these patients be identified and tracked to prevent premature termination of therapy or treatment failure after a full course of initially prescribed therapy. Tracking patient progress and altering treatment prior to premature therapy termination or treatment failure demonstrates accountability to both the patient and third-party payers.
Patient follow-up must be designed to alert the clinician to the patient's treatment status. If the rate of clinical improvement is adequate, no treatment plan modification is indicated and routine follow-up is indicated. If the rate of improvement is less than adequate there may be consideration for altering the treatment plan and increased monitoring. If the patient is not making the expected progress or is clinically worsening, then this would suggest a careful review of the current plan and to consider a new course of action. A patient-focused, practice-based model must also include practical and time-efficient clinical problem-solving tools that equip the clinician to address the patient needs relative to the therapeutic alliance, readiness to change, social support system, relevant community services, and psychiatric consultation. While this study does show some interesting trends for those who are readmitted to CCM, there are several limitations in this investigation that compromise conclusions and outcome generalizations. This was a short, observational, pilot study of the initial results of the implementation of CCM into our practice. There was no control group or randomization. Also, patients may have been lost to follow-up. This study evaluated the current patients and those who recently graduated may have not had enough time since graduation to have symptoms of recurrent depression. Future studies with increased numbers of patients would help confirm findings from this study and further define patient characteristics associated with treatment response and risk for relapse. Future studies with larger cohorts are being planned to determine the level of GAD-7 score and the length of treatment that conveys increased risk or relapse.
Conclusions
Patients who are readmitted to CCM for recurrent depression have a statistically increased risk of associated anxiety symptoms as noted on the GAD-7 at original intake screening, and a longer treatment course prior to remission than those patients who have remained in remission for at least 4 months.
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